Discovering and identifying optimal use of adjuvants - from Sep 9th

Thursday, September 24, 2020 12:00 PM to 4:00 PM · 4 hr. (Africa/Abidjan)
Pre-congress workshops
Vaccine Showcases

Information

Watch on demand on Sep 24, or join LIVE on Sep 9 by registering here:

www.attendee.gotowebinar.com/register/65990897655842318

Workshop leader opening remarks

Dr Wolfgang Leitner, Chief, Innate Immunity Section, Basic Immunology Branch, NIAID, NIH

AS03 adjuvant for COVID-19 vaccine development

Dr Derek O'Hagan, Senior Advisor in R&D, GSK Vaccines

Precision adjuvants: Developing adjuvantation systems tailored to target populations

Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children’s Hospital & Professor, Harvard Medical School

Impacts of Formulation and Delivery on Vaccine Safety and Immunogenicity

Dr Jay Evans, President and CEO, Inimmune Corporation & Director, Center for Translational Medicine, University of Montana

Identification of immune signatures of novel adjuvant formulations using machine learning

Dr Elke S. Bergmann-Leitner, Malaria Vaccine Branch, US Military Malaria Research Program, Walter Reed Army Institute of Research

Programming Multifaceted and Durable Pulmonary T Cell Immunity using combination adjuvants

Dr M. Suresh, John E. Butler Professor of Comparative and Mucosal Immunology, University of Wisconsin-Madison

Perspectives of vaccine adjuvant discovery and development, and funding opportunities for adjuvant research

Dr Wolfgang Leitner, Chief, Innate Immunity Section, Basic Immunology Branch, NIAID, NIH

Next Generation Saponin Adjuvants for Improved Vaccines

Dr Tyler Martin, MD, Chairman, President & CEO, Adjuvance Technologies, Inc.

Panel with all speakers